"Smoke and Mirrors": Trump's Cannabis Rescheduling Order Falls Flat as Opponents Gear Up for Battle.
President Donald Trump recently ordered the Department of Justice to fast-track the rescheduling of cannabis, a move that promised to open doors for research and cut red tape for businesses and consumers. However, behind the scenes, opponents within the administration and conservative groups are fueling resistance to the plan, casting doubt on whether it will ever materialize.
Under the Controlled Substances Act (CSA), drugs are categorized into five schedules based on their potential for harm and medical use. Schedule I substances, like heroin and LSD, are tightly controlled, while Schedule V substances, such as Lyrica, are seen as less harmful. The CSA's scheduling system is notoriously restrictive when it comes to cannabis, which has been lumped into Schedule I despite being used by nearly 20 million Americans.
In December, Trump directed Attorney General Pam Bondi to complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA in the most expeditious manner. However, insiders say that language like "most expeditious manner" may not necessarily mean anything will change anytime soon. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws (NORML), a cannabis advocacy group, expects rescheduling to take years or even decades.
The process is intentionally designed to be slow and laborious, with mechanisms in place that allow opponents to drag it out indefinitely. "If parties want to drag this process out, the mechanisms exist within the administrative process that allow them to do so nearly indefinitely," Armentano said.
Former allies of Trump, including Bill Barr, are now joining forces with anti-cannabis groups like Smart Approaches to Marijuana to challenge the rescheduling plan. These opponents argue that cannabis-based drugs are safer and less addictive than alcohol and tobacco, which are not scheduled at all.
In reality, rescheduling may do little more than give corporations an upper hand in the industry by maintaining restrictive regulations. Corey Coleman, co-founder of Sky High Brands, believes descheduling is the answer to regulatory issues, but acknowledges that it hasn't happened yet.
As the formal rulemaking process continues, opponents are gearing up for a prolonged battle over cannabis rescheduling. The question remains: will Trump's plan actually make a difference in the lives of millions of Americans who use cannabis? Or will it remain smoke and mirrors, fueling division rather than progress?
President Donald Trump recently ordered the Department of Justice to fast-track the rescheduling of cannabis, a move that promised to open doors for research and cut red tape for businesses and consumers. However, behind the scenes, opponents within the administration and conservative groups are fueling resistance to the plan, casting doubt on whether it will ever materialize.
Under the Controlled Substances Act (CSA), drugs are categorized into five schedules based on their potential for harm and medical use. Schedule I substances, like heroin and LSD, are tightly controlled, while Schedule V substances, such as Lyrica, are seen as less harmful. The CSA's scheduling system is notoriously restrictive when it comes to cannabis, which has been lumped into Schedule I despite being used by nearly 20 million Americans.
In December, Trump directed Attorney General Pam Bondi to complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA in the most expeditious manner. However, insiders say that language like "most expeditious manner" may not necessarily mean anything will change anytime soon. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws (NORML), a cannabis advocacy group, expects rescheduling to take years or even decades.
The process is intentionally designed to be slow and laborious, with mechanisms in place that allow opponents to drag it out indefinitely. "If parties want to drag this process out, the mechanisms exist within the administrative process that allow them to do so nearly indefinitely," Armentano said.
Former allies of Trump, including Bill Barr, are now joining forces with anti-cannabis groups like Smart Approaches to Marijuana to challenge the rescheduling plan. These opponents argue that cannabis-based drugs are safer and less addictive than alcohol and tobacco, which are not scheduled at all.
In reality, rescheduling may do little more than give corporations an upper hand in the industry by maintaining restrictive regulations. Corey Coleman, co-founder of Sky High Brands, believes descheduling is the answer to regulatory issues, but acknowledges that it hasn't happened yet.
As the formal rulemaking process continues, opponents are gearing up for a prolonged battle over cannabis rescheduling. The question remains: will Trump's plan actually make a difference in the lives of millions of Americans who use cannabis? Or will it remain smoke and mirrors, fueling division rather than progress?